BioMarin Pharmaceutical (BMRN)
(Delayed Data from NSDQ)
$54.36 USD
-0.78 (-1.41%)
Updated Sep 19, 2025 04:00 PM ET
After-Market: $54.36 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
B Value B Growth B Momentum A VGM
Fundamental Charts
About Cash from Investing (TTM)
The company's trailing twelve month (TTM) Cash from Investing is the sum of the company's past 12 months cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
BMRN 54.36 -0.78(-1.41%)
Will BMRN be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for BMRN based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for BMRN
Why BioMarin Pharmaceutical (BMRN) is a Top Value Stock for the Long-Term
Here's Why BioMarin Pharmaceutical (BMRN) is a Strong Growth Stock
BMRN: What are Zacks experts saying now?
Zacks Private Portfolio Services
Are Options Traders Betting on a Big Move in BioMarin Pharmaceutical Stock?
BioMarin (BMRN) Down 4.6% Since Last Earnings Report: Can It Rebound?
Here's Why BioMarin Pharmaceutical (BMRN) is a Strong Value Stock
Other News for BMRN
Is BMRN coiling for a breakout? NR7 shows up after rising 1.42%
November 21st Options Now Available For BioMarin Pharmaceutical (BMRN)
Is BMRN signaling a buying opportunity? Stochastic Buy Signal shows up after climbing 0.8%
Lower Bollinger Band Walk appears for BMRN after 1.51% move
Raymond James Sticks to Their Buy Rating for BioMarin Pharmaceutical (BMRN)